Zolbetuximab is intended for treating patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma. Credit: meeboonstudio/Shutterstock.com.

The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted Astellas Pharma’s biologics licence application (BLA) for the investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, zolbetuximab.

Zolbetuximab is intended for treating patients with HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are CLDN18.2-positive.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The application is based on data from the Phase III GLOW and SPOTLIGHT clinical trials that assessed zolbetuximab along with other therapies.

The GLOW study evaluated the therapy and CAPOX (a combination chemotherapy including capecitabine and oxaliplatin) against CAPOX and placebo.

SPOTLIGHT assessed zolbetuximab along with mFOLFOX6 (a combination regimen including oxaliplatin, leucovorin and fluorouracil) against mFOLFOX6 and placebo.

A total of 145 patients, and 36 from mainland China, were enrolled for the GLOW and SPOTLIGHT studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of both studies is progression-free survival (PFS). Safety, tolerability, quality-of-life parameters, overall survival, objective response rate and duration of response are their secondary endpoints.

Astellas Immuno-Oncology Development head and senior vice-president Moitreyee Chatterjee-Kishore stated: “China accounts for nearly half of the world’s new cases of gastric cancer, with more than 478,000 new cases diagnosed and more than 373,000 deaths in 2020.

“The CDE’s acceptance of our BLA for zolbetuximab brings us one step closer to having a new therapy available for Chinese patients with advanced-stage disease and in need of treatment options.”

An open-label, multi-centre, randomised Phase II study for treating patients with metastatic pancreatic adenocarcinoma with CLDN18.2-positive tumours is currently underway.

The study intends to assess zolbetuximab along with gemcitabine plus nab-paclitaxel as a first-line treatment.